 |
市場調査レポート
商品コード
873206
CAR-T細胞療法の世界市場：シェア・市場規模・業界分析 - 標的抗原・適応症・地域別 2020年～2026年CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2020 - 2026 |
||||||
| CAR-T細胞療法の世界市場：シェア・市場規模・業界分析 - 標的抗原・適応症・地域別 2020年～2026年 |
|
出版日: 2020年02月01日
発行: Polaris Market Research
ページ情報: 英文 108 Pages
納期: 即日から翌営業日
|
世界のCAR-T細胞療法市場は、2020年から2026年にかけて34.5%のCAGRで推移し、市場規模は2026年までに89億2,000万米ドルに達すると予測されています。CAR-T細胞療法は、患者自身のT細胞を取り出し、遺伝子技術を応用しがん細胞などを攻撃するように作り替えたT細胞を用いる治療法です。多くの企業はより高いシェアを獲得するためにCAR-T細胞療法への投資を開始しています。
当レポートでは、世界のCAR-T細胞療法市場を調査し、市場の概要、標的抗原・適応症・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、業界動向、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。
目次
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 - 2026" provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients' immune cells to fight cancer. The WBCs (white blood cells) are extracted - reengineered - injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
Polaris Market research has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region
CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 - 2026)
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)
CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 - 2026)
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 - 2026)
U.S.
Europe
Japan
Rest of the World
Table of Contents
比較リスト
